Terms: = Pancreatic cancer AND MN1, Q10571, MGCR1-PEN, MGCR1, MGCR, dJ353E16_2, ENSG00000169184, 4330 AND Treatment
12443 results:
1. Highly variable biological effects of statins on cancer, non-cancer, and stem cells in vitro.
Gbelcová H; Rimpelová S; Jariabková A; Macášek P; Priščáková P; Ruml T; Šáchová J; Kubovčiak J; Kolář M; Vítek L
Sci Rep; 2024 May; 14(1):11830. PubMed ID: 38782983
[TBL] [Abstract] [Full Text] [Related]
2. CK2-dependent degradation of CBX3 dictates replication fork stalling and PARP inhibitor sensitivity.
Ma J; Ren D; Wang Z; Li W; Li L; Liu T; Ye Q; Lei Y; Jian Y; Ma B; Fan Y; Liu J; Gao Y; Jin X; Huang H; Li L
Sci Adv; 2024 May; 10(21):eadk8908. PubMed ID: 38781342
[TBL] [Abstract] [Full Text] [Related]
3. ULK1 Mediated Autophagy-Promoting Effects of Rutin-Loaded Chitosan Nanoparticles Contribute to the Activation of NF-κB Signaling Besides Inhibiting EMT in Hep3B Hepatoma Cells.
Wu P; Wang X; Yin M; Zhu W; Chen Z; Zhang Y; Jiang Z; Shi L; Zhu Q
Int J Nanomedicine; 2024; 19():4465-4493. PubMed ID: 38779103
[TBL] [Abstract] [Full Text] [Related]
4. Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials.
Arias-Lorza AM; Costello JR; Hingorani SR; Von Hoff DD; Korn RL; Raghunand N
Sci Rep; 2024 May; 14(1):11570. PubMed ID: 38773189
[TBL] [Abstract] [Full Text] [Related]
5. Inside stent placement is suitable for preoperative biliary drainage in patients with perihilar cholangiocarcinoma.
Yamada R; Kuriyama N; Tanaka T; Nose K; Nakamura Y; Miwata T; Tsuboi J; Mizuno S; Nakagawa H
BMC Gastroenterol; 2024 May; 24(1):174. PubMed ID: 38769494
[TBL] [Abstract] [Full Text] [Related]
6. Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification.
Huai M; Wang Y; Li J; Pan J; Sun F; Zhang F; Zhang Y; Xu L
J Nanobiotechnology; 2024 May; 22(1):257. PubMed ID: 38755645
[TBL] [Abstract] [Full Text] [Related]
7. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
[TBL] [Abstract] [Full Text] [Related]
8. Differentially expressed genes associated with high metabolic tumor volume served as diagnostic markers and potential therapeutic targets for pancreatic cancer.
Kim BG; Lee SH; Jang Y; Kang S; Kang CM; Cho NH
J Transl Med; 2024 May; 22(1):453. PubMed ID: 38741142
[TBL] [Abstract] [Full Text] [Related]
9. Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma.
Kasuga R; Taniki N; Chu PS; Tamura M; Tabuchi T; Yamaguchi A; Hayatsu S; Koizumi J; Ojiro K; Hoshi H; Kaneko F; Morikawa R; Noguchi F; Yamataka K; Usui S; Ebinuma H; Itano O; Hasegawa Y; Abe Y; Kitago M; Inoue M; Nakatsuka S; Jinzaki M; Kitagawa Y; Kanai T; Nakamoto N
Sci Rep; 2024 May; 14(1):10896. PubMed ID: 38740983
[TBL] [Abstract] [Full Text] [Related]
10. Enrichment and Evaluation of Antitumor Properties of Total Flavonoids from
Yang S; Chu G; Wu J; Zhang G; Du L; Lin R
Molecules; 2024 Apr; 29(9):. PubMed ID: 38731467
[TBL] [Abstract] [Full Text] [Related]
11. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of pancreatic Carcinomas: In Search of Therapeutic Targets.
Faber EB; Krause HB; Amin K; Walker P; Hosein PJ; Shields AF; Lenz HJ; Prakash A; Goel S; Oberley M; Malleo G; Luchini C; Hwang J; Florou V; Garrido-Laguna I; Lou E
JCO Precis Oncol; 2024 May; 8():e2300595. PubMed ID: 38723231
[TBL] [Abstract] [Full Text] [Related]
12. Immune checkpoint inhibitor associated diarrhoea.
Al-Hussainy A; Adams J; Simmons J; Kennedy J
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719255
[TBL] [Abstract] [Full Text] [Related]
13. [Analysis of factors affecting the prognosis of patients with pancreatic cancer patients with obstructive jaundice].
Zhang L; Li M; Sun QF; Yu HP
Zhonghua Nei Ke Za Zhi; 2024 May; 63(5):474-479. PubMed ID: 38715484
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
Zhang P; Chen Z; Shi S; Li Z; Ye F; Song L; Zhang Y; Yin F; Zhang X; Xu J; Cheng Y; Su W; Shi M; Fan S; Tan P; Zhong C; Lu M; Shen L
Cancer Immunol Immunother; 2024 May; 73(7):119. PubMed ID: 38713205
[TBL] [Abstract] [Full Text] [Related]
15. treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
Chang JY; Ruff SM; Cloyd JM
Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
[TBL] [Abstract] [Full Text] [Related]
16. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma.
Li F; Si W; Xia L; Yin D; Wei T; Tao M; Cui X; Yang J; Hong T; Wei R
Mol Cancer; 2024 May; 23(1):90. PubMed ID: 38711083
[TBL] [Abstract] [Full Text] [Related]
17. Physical function as a predictor of chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.
Lin KY; Chen PS; Lin CF
BMC Gastroenterol; 2024 May; 24(1):154. PubMed ID: 38711006
[TBL] [Abstract] [Full Text] [Related]
18. QbD Enabled Development and Evaluation of Pazopanib Loaded Nanoliposomes for PDAC treatment.
Shinde A; Panchal K; Patra P; Singh S; Enakolla S; Paliwal R; Chaurasiya A
AAPS PharmSciTech; 2024 May; 25(5):97. PubMed ID: 38710894
[TBL] [Abstract] [Full Text] [Related]
19. Bilateral efforts to improve SERS detection efficiency of exosomes by Au/Na
Zhao Q; Cheng X; Hu S; Zhao M; Chen J; Mu M; Yang Y; Liu H; Hu L; Zhao B; Song W
Biosens Bioelectron; 2024 Aug; 258():116349. PubMed ID: 38705072
[TBL] [Abstract] [Full Text] [Related]
20. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
[TBL] [Abstract] [Full Text] [Related]
[Next]
